Expression of L1 cell adhesion molecule is a significant prognostic factor in pT3-stage gastric cancer

Anticancer Research

Volumn 29, Issue 10, 2009, Pages 4033-4039

  Kodera, Yasuhiro ^a   Nakanishi, Hayao ^b   Ito, Seiji ^b   Misawa, Kazunari ^b   Ito, Yuichi ^a   Nakayama, Goro ^a   Koike, Masahiko ^a   Fujiwara, Michitaka ^a   Yamamura, Yoshitaka ^b   Nakao, Akimasa ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Gastric cancer; L1; Metastasis; Prognostic factor

Indexed keywords

ANTIBODY; NERVE CELL ADHESION MOLECULE L1;

ADULT; ARTICLE; CANCER GROWTH; CANCER STAGING; CARCINOMATOSIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PERITONEAL CAVITY; PERITONEUM METASTASIS; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CANCER; SURVIVAL RATE;

FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEURAL CELL ADHESION MOLECULE L1; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 71949100682     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Pisani P, Parkin DM, Bray F and Ferlay J: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83: 18-29, 1999.
2. Yokota T, Ishiyama S, Saito T, Teshima S, Shimotsuma M and Yamauchi H: Treatment strategy of limited surgery in the treatment guidelines for gastric cancer in Japan. Lancet Oncol 4: 423-428, 2003. (Pubitemid 36833684)
3. Maehara Y, Hasuda S, Koga T, Tokunaga E, Kakeji Y and Sugimachi K: Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg 87: 353-357, 2000. (Pubitemid 30156364)
4. Yoo CH, Noh SH, Shin DW, Choi SH and Min JS: Recurrence following curative resection for gastric carcinoma. Br J Surg 87: 236-252, 2000.
5. Kodera Y, Nakanishi H, Ito S, Mochizuki Y, Ohashi N, Yamamura Y, Fujiwara M, Koike M, Tatematsu M and Nakao A: Prognostic significance of intraperitoneal cancer cells in gastric carcinoma: analysis of real-time reverse transcriptase-polymerase chain reaction after 5 years of follow-up. J Am Coll Surg 202: 231-236, 2006. (Pubitemid 43112481)
6. Raveh S, Gavert N and Ben-Ze'ev A: L1 cell adhesion molecule (L1CAM) in invasive tumors. Cancer Utt 2009, in press
7. Fogel M, Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Smirnov A, Edler L, Ben-Arie A, Huszar M and Altevogt P: L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinoma. Lancet 362: 869-875, 2003. (Pubitemid 37130096)
8. Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, McLendon RE, Hjelmeland AB and Rich JN: Targeting cancer stem cells through LlCAM suppresses glioma growth. Cancer Res 68: 6043-6048, 2008.
9. Allory Y, Matduoka Y, Bazille C, Christensen EI, Ronco P, and Debiec H: The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinoma. Clin Cancer Res 11: 1190-1197, 2005. (Pubitemid 40175770)
10. Meier F, Busch S, Gast D, Goeppert A, Altevogt P, Maczey E, Riedle S, Garbe C and Schittek B: The adhesion molecule L1 (CD171) promotes melanoma progression. Int J Cancer 119: 549-555, 2006. (Pubitemid 43955707)
11. Kaifi JT, Zinnkann U, Yekebas EF, Schurr PG, Reichelt U, Wachowiak R, Fiegel HC, Petri S, Schachner M and Izbicki JR: L1 is a potential marker for poorly-differentiated pancreatic endocrine carcinoma. World J Gastroenterol 12: 94-98, 2006. (Pubitemid 43126090)
12. Kaifi JT, Reichelt U, Quaas A, Schurr PG, Wachowiak R, Yekebas EF, Strate T, Schneider C, Pantel K, Schachner M, Sauter G and Izbicki JR: L1 is associated with micrometastatic spread and poor outcome in colorectal cancer. Mod Pathol 20: 1183-1190, 2007. (Pubitemid 47609067)
13. Boo YJ, Park JM, Kim J, Chae YS, Min BW, Um JW and Moon HY: L1 expression as a marker of poor prognosis, tumor progression and short survival in patients with colorectal cancer. Ann Surg Oncol 14: 1703-1711, 2007. (Pubitemid 46790990)
14. Gavert N, Concacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T and Ben-Ze'ev A: L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol 168: 633-642, 2005. (Pubitemid 40271028)
15. Arlt MJ, Novak-Hofer I, Gast D, Gschwend V, Moldenhauer G, Grunberg J, Honer M, Schubiger PA, Altevogt P and Krueger A: Efficient inhibition of intraperitoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1 cell adhesion molecule monoclonal antibody treatment. Cancer Res 66: 936-943, 2006. (Pubitemid 43165961)
16. Sato T, Murakumo Y, Hagiwara S, Jijiwa M, Suzuki C, Yatabe Y and Takahashi M: High-level expression of CD109 is frequently detected in lung squamous cell carcinomas. Pathol Int 57: 719-724, 2007. (Pubitemid 47537632)
17. Gast D, Riedle S, Kiefel H, Muerkoster SS, Schaefer H, Schaefer MK and Altevogt P: The RGD integrin binding site in human L1-CAM is important for nuclear signaling. Exper Cell Res 314: 2411-2418, 2008.
18. Gast D, Riedle S, Issa Y, Pfeifer M, Beckhove P, Sanderson MP, Arlt M, Moldenhauer G, Fogel M, Krueger A and Altevogt P: The cytoplasmic part of Ll-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies. Oncogene 27: 1281-1289, 2008. (Pubitemid 351294696)
19. Issa Y, Nummer D, Seibel T, Muerkoster SS, Koch M, Schmidz-Winnenthal FH, Galindo L, Weitz J, Beckhove P and Altevogt P: Enhanced LlCAM expression on pancreatic tumor endothelium mediates selective tumor cell transmigration. J Mol Med 87: 99-112, 2009.
20. Sebens-Muerkoster S. Werbing V, Sipos B, Debus MA, Witt M, Grossmann M, Uisner D, Kotteritzsch J, Kappes H, Kloppel G, Altevogt P, Flosch UR and Schafer H: Drug-induced expression of the cellular adhesion molecule LlCAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene 26: 2759-2768, 2007. (Pubitemid 46663831)
21. Sebens-Muerkoster S, Koetteritzsch J, Geismann C, Gast D, Kruse ML, Altevogt P, Foelsch UR and Schaefer J: Alpha5-integrin is crucial for L1CAM-mediated chemoresistance in pancreatic adenocarcinoma. Int J Oncol 34: 243-253, 2009.